Evoked Potentials to Test a Treatment of Chronic Multiple Sclerosis

Anderson, David C.; Slater, Gerald E.; Sherman, Robert S.; Ettinger, Milton G.

doi:10.1001/archneur.1987.00520240014005

Cited by 47 publications

(24 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results showed no difference between cytokine levels of male and female patients similar to results of Eikelenboom et al (8). Unilaterally or, more frequently, bilaterally prolonged VEP P100 latencies were present in 65.0% of our patients, which was similar to results of previous studies (1,4,5). Evoked potentials are frequently used to confirm the diagnosis of MS.…”

Section: Discussionsupporting

confidence: 92%

“…Various studies investigating relationships between the evoked potential latencies and the disability scores in MS gave opposite results. Some studies demonstrated that the expanded disability status scale (EDSS) scores increased parallel to delays in visual evoked potentials (VEP) (2,3), however others found no correlation between disability scores and change in the VEP latencies (4,5). Magnetic resonance imaging (MRI) often demonstrates new lesions independent of clinical status (6).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Multiple Sclerosis: Relationships Between Cytokines, MRI Lesion Burden, Visual Evoked Potentials and Disability Scores

et al. 2010

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Introductionmentioning

confidence: 99%

Multiple Sclerosis: Relationships Between Cytokines, MRI Lesion Burden, Visual Evoked Potentials and Disability Scores

et al. 2010

View full text Add to dashboard Cite

show abstract

“…In our study, VEP abnormality was the most commonly encountered defect. EPs have been used to investigate the natural progression of diseases and the efficacies of treatment methods (20,21,22,23,24,25). While some studies reported weak or no correlation between clinical and EP changes, some studies reported moderate correlations (20,21,22,25).…”

Section: Discussionmentioning

confidence: 99%

Clinical, Radiological and Electrophysiological Comparison of Immunomodulatory Therapies in Multiple Sclerosis

Genç¹,

Demirkaya

Bek

et al. 2017

Arch Neuropsychiatr

View full text Add to dashboard Cite

Multiple sclerosis (MS) is an autoimmune inflammatory demyelinating disease of the central nervous system (CNS) usually presenting with episodes of relapses and remissions, and sometimes progression of the disease can be triggered by environmental factors and the genetic background (1). Magnetic resonance imaging (MRI) provides significant data in MS regarding diagnosis, demonstration of the clinical-lesion relationship, disease activity and treatment follow-up (2). Examination of evoked potentials (EPs) is a simple and non-invasive method that is important in confirming clinical signs and symptoms as well as revealing silent lesions and multisystem involvement. Visual evoked potentials (VEPs), brainstem auditory evoked potentials (BAEPs), and somatosensory evoked potentials (SEPs) are used to electrophysiologically define lesions in CNS afferent pathways, and they reveal the multifocal characteristics of the disease.Because episodes might recover on their own and progression varies among patients or even in the same patient over time, it is difficult to decide whether treatment in MS is effective in the short run. Treatment interventions vary depending on the disease type and clinical period. In all randomized, placebo-controlled studies, interferon beta (IFN-B) and glatiramer acetate (GA) have been shown to reduce the frequency of episodes and MRI activity in relapsing-remitting multiple sclerosis (RRMS). These treatments should be given to patients diagnosed with RRMS with an Expanded Disability Status Scale (EDSS) score <5.5 who have had two or more episodes lasting longer than 24 hours with new symptoms or deterioration of previous symptoms and no fever. Debates as to which agent should be selected for which patient, the time to start treatment, the duration of treatment, and the roles of side effects in efficacy are ongoing. We aimed to compare these agents in terms of clinical, radiological, and electrophysiological measurements and to determine whether these agents showed any differences in efficacy or side effects. METHODS Study PopulationWe chose a cohort of 85 patients older than 18 years of age who applied to the MS outpatient clinic of the Gülhane Military Medical Academy between April 2006 and April 2009 and who were being followed up with a "Clinically Definite MS" diagnosis according to the Poser and Introduction: Although it has been shown that immunomodulatory therapies (IMTs) in multiple sclerosis (MS) can modify the course of the disease by reducing the relapse rate and delaying the progression of disability, no study comparing IMTs head-to-head in terms of clinical, radiological, and electrophysiological changes is available. We aimed to investigate the effects of interferon-beta (IFN-B) 1b, IFN-B-1a subcutaneous (sc), IFN-B-1a intramuscular (im), and glatiramer acetate (GA) therapies on clinical, electrophysiological, and radiological findings. Methods:We studied a cohort of 85 MS patients who were followed up for at least 2 years and had complete charting, including pre-treatment and post-...

show abstract

“…Stable patients are electrophysiologically stable [9,24], whereas progression of disability seems to be associated with a progressive increase in latency [9,30]; no or poor correlations can be found with clinical symptoms [1,2,12,24]. In a long-term followup of chronic progressive azathioprine-methylprednisolone-treated MS patients, Nuwer et al [20] were able to find a correlation between latency changes and clinical outcome.…”

Section: Discussionmentioning

confidence: 99%

“…The diagnostic value of Evoked Potentials (EPs) in Multiple Sclerosis (MS) is well known [5,8,11,17,22], but their usefulness in disease monitoring is controversial [1,2,16,20]. Steroids are widely used in the treatment of MS exacerbations, but is still uncertain if their mechanisms of action are mainly antiedemic [14], antiinflammatory [6] or something else [3,29].…”

Section: Introductionmentioning

confidence: 99%

Serial evoked potentials in multiple sclerosis bouts. Relation to steroid treatment

et al. 1994

View full text Add to dashboard Cite

Serial recordings of multimodal sensory (visual, acoustic and somatosensory) evoked potentials were made in 19 relapsing-remitting Multiple Sclerosis patients enrolled in a clinical trial designed to evaluate the efficacy of dexamethasone versus high- and low-dose methylprednisolone in acute multiple sclerosis bouts. Electrophysiological and clinical evaluations were performed at the onset of therapy and until 6 months after the end of treatment. Using an arbitrary Evoked Potentials score that takes into account both latency and waveform alterations, we found a positive correlation between evoked potentials and clinical disability scores. Furthermore, different electrophysiological profiles were detected in the three therapeutic subgroups. Evoked potentials may be useful for monitoring acute Multiple Sclerosis bouts and evaluating the effect of therapy.

show abstract

Evoked Potentials to Test a Treatment of Chronic Multiple Sclerosis

Cited by 47 publications

References 15 publications

Multiple Sclerosis: Relationships Between Cytokines, MRI Lesion Burden, Visual Evoked Potentials and Disability Scores

Multiple Sclerosis: Relationships Between Cytokines, MRI Lesion Burden, Visual Evoked Potentials and Disability Scores

Clinical, Radiological and Electrophysiological Comparison of Immunomodulatory Therapies in Multiple Sclerosis

Serial evoked potentials in multiple sclerosis bouts. Relation to steroid treatment

Contact Info

Product

Resources

About